- Home
- OCS vs ALLO Comparison
OCS vs ALLO Comparison
Compare OCS & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OCS | ALLO |
|---|---|---|
| Founded | 2003 | 2017 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 732.4M | 597.7M |
| IPO Year | 2022 | 2018 |
Fundamental Metrics
Financial Performance| Metric | OCS | ALLO |
|---|---|---|
| Price | $10.07 | $1.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 15 |
| Target Price | ★ $42.00 | $8.35 |
| AVG Volume (30 Days) | 142.9K | ★ 4.9M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.09 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $466.06 | N/A |
| Revenue Next Year | $479.73 | $142,416.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.50 | $1.04 |
| 52 Week High | $34.48 | $4.46 |
Technical Indicators
Market Signals| Indicator | OCS | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 24.29 | 38.77 |
| Support Level | N/A | $1.59 |
| Resistance Level | $13.49 | $1.92 |
| Average True Range (ATR) | 0.53 | 0.10 |
| MACD | -0.21 | -0.03 |
| Stochastic Oscillator | 3.42 | 16.51 |
Price Performance
Historical ComparisonAbout OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).